VEGFA and retinopathy of prematurity: The most commonly anti-VEGF agent used in preterm infants is bevacizumab and it has great evidence of successful outcomes for the treatment of threshold ROP either as a single treatment or as an adjuvant to standard laser therapy (66, 67, 72).